Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Presidio Pharmaceuticals

Request full access

Discovers, develops and commercializes novel therapeutics for viral infections, including HCV and HIV

San Francisco, United StatesFounded 2006Biotech & Life Sciences

About Presidio Pharmaceuticals

Presidio Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company established in 2006, with its headquarters in San Francisco, California. The company was founded by Omar Haffar, who also served as President and CEO. From its inception, Presidio focused on developing small-molecule antiviral therapeutics. Initially targeting the HIV market, the company shifted its primary focus to the underserved Hepatitis C virus (HCV) market, which demonstrated significant funding potential.

The company's business model centers on the discovery, development, and subsequent licensing of its drug candidates. Presidio strategically forms partnerships and out-licensing agreements for its programs. This is evident in its collaborations with companies like Boehringer Ingelheim for clinical trials and licensing agreements with Pharco Pharmaceuticals for distribution in Egypt and the MENA region, and Ascletis for the Chinese market. A significant milestone was the 2016 licensing of its lead compound, ravidasvir, to the Drugs for Neglected Diseases initiative (DNDi) for use in low- and middle-income countries.

Presidio's lead product is ravidasvir (formerly PPI-668), a potent, pan-genotypic NS5A inhibitor for treating HCV. The drug is designed for convenient once-daily oral dosing and can be used in combination with other antiviral classes to combat resistance. Clinical trials for ravidasvir, particularly in combination with sofosbuvir, have shown high efficacy, with a 97% cure rate for Hepatitis C patients. These successful trials led to the treatment receiving conditional registration in Malaysia in 2021, full approval in 2024, and its inclusion in the WHO's Essential Medicines List in 2023.

Financially, Presidio has navigated several funding rounds to support its clinical programs. The company raised a total of $91.9 million over seven rounds, including a notable $26 million Series B in August 2007 and a $21.8 million Series C in June 2014. Its investor syndicate includes prominent venture capital firms such as New Leaf Venture Partners, Panorama Capital, Bay City Capital, and Baker Brothers Investments.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
23.0/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Infections and Infectious Diseases, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

7 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES DOther financing Jun 2014 $22M $87M Undisclosed —
EARLY VCOther financing Oct 2012 $8M $32M Undisclosed —
Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Growth signals

Presidio Pharmaceuticals website traffic

Latest recorded traffic for Presidio Pharmaceuticals is 910 monthly website visits, up 30% over the last three months.

Latest monthly visits910 3-month web change+30%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Presidio Pharmaceuticals in the San Francisco ecosystem

Live from Dealroom

The Presidio Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

  • Panorama Capital
  • Ventures West
  • Bay City Capital
  • Nexus Medical Partners

Series B and later1 investor entered at this stage

  • New Leaf Venture Partners

Other known investors1 additional known investor

  • Stanford University
Team profiled 8 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · San Francisco HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Presidio Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Presidio Pharmaceuticals’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.